Eficacia y seguridad de los antagonistas del factor de necrosis tumoral en la enfermedad de Crohn: meta-análisis de ensayos controlados con placebo

Categoría Resumen estructurado de revisiones sistemáticas
RevistaDatabase of Abstracts of Reviews of Effects (DARE)
Año 2010
Cargando información sobre las referencias

CRD SUMMARY:

This review assessed the safety and efficacy of tumour necrosis factor antagonists for Crohn's disease. The authors concluded that infliximab, adalimumab and certolizumab were effective and safe in luminal Crohn's disease. This was a generally well-conducted review and the authors' conclusions appear to be supported by the data
Epistemonikos ID: e02874c142f34d21f0aeb3392235a93b3ff1a75e
First added on: Jun 07, 2012